JP2011148742A - Cell activator and skin external preparation - Google Patents

Cell activator and skin external preparation Download PDF

Info

Publication number
JP2011148742A
JP2011148742A JP2010012157A JP2010012157A JP2011148742A JP 2011148742 A JP2011148742 A JP 2011148742A JP 2010012157 A JP2010012157 A JP 2010012157A JP 2010012157 A JP2010012157 A JP 2010012157A JP 2011148742 A JP2011148742 A JP 2011148742A
Authority
JP
Japan
Prior art keywords
fucoxanthin
external preparation
extract
skin
cell activator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010012157A
Other languages
Japanese (ja)
Inventor
Hitomi Hase
仁美 長谷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Noevir Co Ltd
Original Assignee
Noevir Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noevir Co Ltd filed Critical Noevir Co Ltd
Priority to JP2010012157A priority Critical patent/JP2011148742A/en
Publication of JP2011148742A publication Critical patent/JP2011148742A/en
Pending legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide a cell activator and a skin external preparation which synergistically improve the skin beautifying effect by fucoxanthin and exhibits high cell activation. <P>SOLUTION: The cell activator and the skin external preparation comprise fucoxanthin of component (A) and almond and/or peppermint of component (B). <P>COPYRIGHT: (C)2011,JPO&INPIT

Description

細胞賦活効果が相乗的に向上し、老化防止効果に優れた細胞賦活剤及び皮膚外用剤に関する。   The present invention relates to a cell activator and an external preparation for skin which have a synergistic improvement in cell activation effect and an excellent anti-aging effect.

加齢、紫外線、ストレスなどによるシワ、シミ、皮膚の弾性低下といった皮膚症状の要因として、細胞機能低下などが挙げられる。このような皮膚症状を防止・改善するために、様々な有効成分の検索及び配合検討が従来なされてきた。細胞賦活剤としては、ポンカンのエッセンス(特許文献1参照)、雪嶺茸抽出物(特許文献2参照)、フサザクラ科植物の抽出物(特許文献3参照)、オオズキンカブリタケの抽出物(特許文献4参照)等、さまざまな天然由来の成分が報告されている。   As a factor of skin symptoms such as wrinkles, stains, and skin elasticity reduction due to aging, ultraviolet rays, stress, etc., there is a decrease in cell function. In order to prevent and ameliorate such skin symptoms, search for various active ingredients and formulation studies have been conventionally conducted. Examples of cell activators include ponkan essence (see Patent Document 1), snow lees extract (see Patent Document 2), Fusaza cherry plant extract (see Patent Document 3), and Ozukin Kaburitake extract (Patent Document). 4)) and other naturally-derived components have been reported.

また、フコキサンチンは、褐藻類、特にコンブに多く含まれるカロテノイドの一種である。このフコキサンチンが、通常は褐色脂肪細胞に特異的に存在するタンパク質であるサーモゲニン(Thermogenin;熱産生タンパク質)のUCP1(uncoupling protein 1)の発現を白色脂肪細胞において促すことで、脂肪組織における脂肪の燃焼を助けること(非特許文献1参照)、中性脂肪の吸収を調整すること(特許文献5参照)や、エラスターゼやヒアルロニダーゼ等の阻害活性を有する美肌効果(特許文献6参照)が知られている。   Fucoxanthin is a kind of carotenoid that is contained in abundance of brown algae, especially kombu. This fucoxanthin promotes the expression of UCP1 (uncoupling protein 1) of thermogenin (thermogenin), a protein normally present in brown adipocytes, in white adipocytes. Known to assist combustion (see Non-Patent Document 1), to adjust the absorption of neutral fat (see Patent Document 5), and to beautify skin with inhibitory activities such as elastase and hyaluronidase (see Patent Document 6). Yes.

Maeda H,Hosokawa M,Sashima T,Funayama K.Miyashita K (2005)."Fucoxanthin from edible seaweed, Undaria pinnatifida, shows antiobesity effect thyough UCP1 expression in white adipose tissues.".Biochem Biophys Res Commun 332 (2):392-7.Maeda H, Hosokawa M, Sashima T, Funayama K.Miyashita K (2005). "Fucoxanthin from edible seaweed, Undaria pinnatifida, shows antiobesity effect thyough UCP1 expression in white adipose tissues.". Biochem Biophys Res Commun 332 (2): 392 -7.

特開2001−131045号公報JP 2001-131045 A 特開2007−70306号公報JP 2007-70306 A 特開2007−84443号公報JP 2007-84443 A 特開2008−222664号公報JP 2008-222664 A 特開2008−231057号公報JP 2008-231057 A 特開2008−291004号公報JP 2008-291004 A

しかしながら、化学合成や遺伝子組換などの手法によるフコキサンチンの生産が現在のところ不可能なため、供給源が褐藻のみであること、加えて褐藻中に含まれるフコキサンチン量は、多いものでも乾燥重量の0.1%程度であるため、フコキサンチンのみを有効量配合するのは困難な状況であった。そこで、本発明においては、フコキサンチンによる美肌効果を相乗的に向上させ、高い細胞賦活作用を発揮する細胞賦活剤及び皮膚外用剤を提供することを目的とした。   However, production of fucoxanthin by methods such as chemical synthesis and genetic recombination is currently impossible, so the source is only brown algae, and in addition, even if the amount of fucoxanthin contained in brown algae is large, it is dry Since it was about 0.1% of the weight, it was difficult to blend only an effective amount of fucoxanthin. Therefore, an object of the present invention is to provide a cell activator and a skin external preparation that synergistically improve the skin beautifying effect of fucoxanthin and exhibit a high cell activation action.

本願発明は、成分(A)フコキサンチンと、成分(B)アーモンド及び/又はペパーミントを含有してなる細胞賦活剤及び皮膚外用剤に関する。   The present invention relates to a cell activator and an external preparation for skin comprising component (A) fucoxanthin and component (B) almond and / or peppermint.

本発明の細胞賦活剤及び皮膚外用剤は、成分(A)フコキサンチン及びフコキサンチンを含有する褐藻類と、成分(B)アーモンド及び/又はペパーミントを併用して用いることにより、細胞賦活効果が相乗的に向上し、高い老化防止効果を発揮する。   The cell activator and the external preparation for skin of the present invention have a synergistic cell activation effect by using a combination of component (A) fucoxanthin and brown algae containing fucoxanthin and component (B) almond and / or peppermint. It improves and improves the anti-aging effect.

本発明の細胞賦活剤及び皮膚外用剤は、成分(A)フコキサンチン及びフコキサンチンを含有する褐藻類と、成分(B)アーモンド及び/又はペパーミントを併用して用いる。これらの成分に関し、個々に説明する。   The cell activator and the external preparation for skin of the present invention are used in combination with component (A) fucoxanthin and brown algae containing fucoxanthin and component (B) almond and / or peppermint. These components will be described individually.

本発明で用いるフコキサンチン(Fucoxanthin)は、下記化学式(1)で表されるカロテノイドの一つであり、褐藻やその他の不等毛藻に存在して茶色-オリーブ色を呈するとともに、葉緑体において光合成の補助色素として機能している。特に、褐藻類中のカロテノイドのほぼ100%がフコキサンチンであるといわれている。   Fucoxanthin used in the present invention is one of the carotenoids represented by the following chemical formula (1), is present in brown algae and other unequal hairy algae and exhibits a brown-olive color, and also has a chloroplast. Functions as an auxiliary dye for photosynthesis. In particular, almost 100% of carotenoids in brown algae are said to be fucoxanthin.

Figure 2011148742
Figure 2011148742

本発明においては、精製されたフコキサンチンを用いても、フコキサンチンを含有する褐藻若しくはその抽出物を用いても良い。   In the present invention, purified fucoxanthin may be used, or brown algae containing fucoxanthin or an extract thereof may be used.

フコキサンチンを含有する褐藻類としては、特に限定されないが、例えばモズク科(Spermatochnaceae)モズク(イトモズク,Nemacystus decipiens)、オキナワモズク(Cladosiphon okamuranus T.;Eudesme virescens J.AG.)、コンブ科(Laminariaceae)マコンブ(Laminaria japonica)、アラメ(Eisenia bicyclis)、チガイソ科(Alariaceae)ワカメ(Undaria pinnatifida)、ホンダワラ科(Sargassaceae)ホンダワラ(Sargassum fulvellum)、ヒジキ(Sargassum fusiforme)等が例示される。これらの中でもフコキサンチンの含有量の点からマコンブを用いることが最も好ましい。   The brown algae containing fucoxanthin are not particularly limited. For example, Spermatochnaceae mozuku (Nemacystus decipiens), Okinawa mozuku (Cladosiphon okamuranus T.; Eudesme virescens J.AG.), Kombu (Laminariaceae) Examples include Macombu (Laminaria japonica), Alamece (Eisenia bicyclis), Chileaceae (Alariaceae) wakame (Undaria pinnatifida), Honda (Sargassaceae) Honda (Sargassum fulvellum), and hydrangea (Sargassum fusiforme). Among these, it is most preferable to use macombu in view of the content of fucoxanthin.

本発明で使用するアルモンドは、バラ科(Rosaceae)サクラ属(Prunus L.)植物のアルモンド(別名 へん桃,Prunus amygdalus Batch)の種子部分をそのままあるいは乾燥又は粉砕後、溶媒で抽出したものを用いる。   As the almond used in the present invention, the seed part of the almond (also known as Prunus amygdalus Batch) of the Rosaceae (Prunus L.) plant is used as it is or after being dried or ground and then extracted with a solvent. .

本発明で用いるペパーミント(Mentha arvensis L. var. piperascens Malin.)は、シソ科(Labiatae)に属する多年草で、その同属植物である、セイヨウハッカ(Mentha piperita L.)、ミドリハッカ(Mentha viridis L.)を用いることもできる。ペパーミントは、葉,茎,花等各部位を用いることができるが、地上部の全体若しくは葉を用いることが好ましい。   Peppermint (Mentha arvensis L. var. Piperascens Malin.) Used in the present invention is a perennial belonging to the Labiatae family, and is a plant belonging to the same genus, Mentha piperita L., Mentha viridis L. Can also be used. Peppermint can use various parts such as leaves, stems, flowers, etc., but it is preferable to use the whole ground part or leaves.

本発明の細胞賦活剤、皮膚外用剤において、上記の藻類、植物は、そのまま用いることもできるが、溶媒による抽出物を用いることもできる。抽出溶媒としては、水の他、メタノール、エタノール、プロパノール、イソプロパノール等の低級アルコール、1、3−ブチレングリコール、プロピレングリコール、ジプロピレングリコール、グリセリン等の多価アルコール、エチルエーテル、プロピルエーテル等のエーテル類、酢酸ブチル、酢酸エチル等のエステル類、アセトン、エチルメチルケトン等のケトン類などの溶媒を用いることができ、これらより1種又は2種以上を選択して用いる。また、生理食塩水、リン酸緩衝液、リン酸緩衝生理食塩水等を用いてもよい。さらに、水や二酸化炭素、エチレン、プロピレン、エタノール、メタノール、アンモニアなどの1種又は2種以上の超臨界流体や亜臨界流体を用いてもよい。また、オートクレーブなどを用いて、加圧下で抽出することも可能である。   In the cell activator and the external preparation for skin of the present invention, the algae and plants can be used as they are, but an extract using a solvent can also be used. Extraction solvents include water, lower alcohols such as methanol, ethanol, propanol and isopropanol, polyhydric alcohols such as 1,3-butylene glycol, propylene glycol, dipropylene glycol and glycerin, ethers such as ethyl ether and propyl ether. And solvents such as esters such as butyl acetate and ethyl acetate, and ketones such as acetone and ethyl methyl ketone can be used, and one or more of these can be selected and used. Further, physiological saline, phosphate buffer, phosphate buffered saline, or the like may be used. Furthermore, you may use 1 type, or 2 or more types of supercritical fluids and subcritical fluids, such as water, a carbon dioxide, ethylene, propylene, ethanol, methanol, ammonia. It is also possible to extract under pressure using an autoclave or the like.

藻類、植物の上記溶媒による抽出物は、そのままでも使用することができるが、濃縮、乾固した物を水や極性溶媒に再度溶解して使用することもでき、これらの生理作用を損なわない範囲で脱色、脱臭、脱塩等の精製処理やカラムクロマトグラフィー等による分画処理を行った後に用いてもよい。植物の前記抽出物やその処理物及び分画物は、各処理及び分画後に凍結乾燥し、用時に溶媒に溶解して用いることもできる。   Extracts of the above-mentioned solvents of algae and plants can be used as they are, but the concentrated and dried solids can be used again by dissolving them in water or a polar solvent, and their physiological functions are not impaired. It may be used after performing purification treatment such as decolorization, deodorization and desalting, and fractionation treatment by column chromatography. The said extract of plant, its processed material, and a fraction can also be lyophilized | freeze-dried after each process and fractionation, and can also be used after melt | dissolving in a solvent at the time of use.

本発明の皮膚外用剤には、上述の必須成分の他に、必要に応じて、通常、医薬品、医薬部外品、皮膚化粧料、毛髪用化粧料及び洗浄料に配合される、油性成分、保湿剤、粉体、色素、乳化剤、可溶化剤、洗浄剤、紫外線吸収剤、増粘剤、薬剤、香料、樹脂、防菌防黴剤、アルコール類等を適宜配合することができる。また、本発明の効果を損なわない範囲において、他の細胞賦活剤、コラーゲン産生促進剤、美白剤、抗酸化剤及び脂肪蓄積抑制剤との併用も可能である。   In addition to the above-mentioned essential components, the external preparation for skin of the present invention, if necessary, is an oily component that is usually blended in pharmaceuticals, quasi drugs, skin cosmetics, hair cosmetics, and cleansing agents, Moisturizers, powders, pigments, emulsifiers, solubilizers, cleaning agents, ultraviolet absorbers, thickeners, drugs, fragrances, resins, antibacterial and antifungal agents, alcohols, and the like can be appropriately blended. Moreover, in the range which does not impair the effect of this invention, combined use with another cell activator, a collagen production promoter, a whitening agent, an antioxidant, and a fat accumulation inhibitor is also possible.

また、本発明の細胞賦活剤は、皮膚や毛髪に外用するだけではなく、経口摂取も可能であることより、任意の飲食品、または医薬品に応用することも可能である。ここでいう飲食品には、機能性食品及び栄養補助食品も含まれる。   In addition, the cell activator of the present invention can be applied not only to the skin and hair but also to oral intake, so that it can be applied to any food or drink or medicine. The food and drink here includes functional foods and nutritional supplements.

さらに実施例により、本発明の特徴について詳細に説明する。まず、フコキサンチンとアーモンド、ペパーミントを併用した際の細胞賦活作用の評価について記載する。   Further, the features of the present invention will be described in detail by way of examples. First, it describes about evaluation of the cell activation effect | action at the time of using fucoxanthin, an almond, and peppermint together.

(試料)
1.フコキサンチン
オリザ油化株式会社製、商品名フコキサンチン−WSPC0.1を用いた。
2.アーモンド抽出物
Silab社製、商品名ポリリフトを用いた。
3.ペパーミント抽出物
丸善製薬社製商品名ペパーミント抽出液LAを用いた。
(sample)
1. Fucoxanthin Oriza Yuka Co., Ltd. product name Fucoxanthin-WSPC0.1 was used.
2. Almond extract The product name polylift made by Silab was used.
3. Peppermint extract The trade name Peppermint extract LA manufactured by Maruzen Pharmaceutical Co., Ltd. was used.

[ヒト表皮角化細胞賦活作用]
ヒト表皮角化細胞株HaCaTを1ウェル当り2.0×10個となるように96ウェルマイクロプレートに播種した。播種培地には、ダルベッコ改変イーグル培地(DMEM)に5質量%のウシ胎児血清(FBS)を添加したものを用いた。24時間培養後、培地を、5質量%FBS添加DMEM培地にて表1に示す各試料濃度に調整したサンプル培養液に交換し、更に24時間培養した。培養後、サンプル培養液を、MTT試薬を100μg/mL含有するように調整した培地に交換し、更に2時間培養した。生じたフォルマザンを2−プロパノールで抽出し、マイクロプレートリーダーで550nmの吸光度を測定した。同時に濁度として650nmの吸光度を測定し、両測定値の差によってHaCaT(表皮角化細胞)に対する細胞賦活作用を評価した。なお、サンプル培養液の代わりに1質量%FBS添加DMEM培地を用いたものをコントロールとした。結果を表1にあわせて示す。
[Human epidermal keratinocyte activation]
A human epidermal keratinocyte cell line HaCaT was seeded in a 96-well microplate so as to be 2.0 × 10 4 cells per well. The seeding medium used was Dulbecco's modified Eagle medium (DMEM) supplemented with 5% by weight fetal bovine serum (FBS). After culturing for 24 hours, the medium was replaced with a sample culture solution adjusted to each sample concentration shown in Table 1 in 5% by mass FBS-added DMEM medium, and further cultured for 24 hours. After culturing, the sample culture medium was replaced with a medium adjusted to contain 100 μg / mL of MTT reagent, and further cultured for 2 hours. The resulting formazan was extracted with 2-propanol, and the absorbance at 550 nm was measured with a microplate reader. At the same time, the absorbance at 650 nm was measured as turbidity, and the cell activation effect on HaCaT (epidermal keratinocytes) was evaluated by the difference between the two measured values. In addition, what used 1 mass% FBS addition DMEM culture medium instead of the sample culture solution was used as control. The results are shown in Table 1.

[ヒト真皮線維芽細胞賦活作用]
正常ヒト真皮線維芽細胞を1ウェル当り2.0×10個となるように96ウェルマイクロプレートに播種した。播種培地には1質量%のウシ胎児血清(FBS)を添加したダルベッコ改変イーグル培地(DMEM)を用いた。24時間後、1質量%FBS添加DMEM培地にて表1に示す濃度に調整したサンプル培養液に交換し、さらに48時間培養した。次に400μg/mLとなるよう培地にて調整したMTT試薬を、上清を除いた細胞に添加し、約2時間培養した。最後に2−プロパノールにて生じたフォルマザンを抽出し、550nmの吸光度を測定した。同時に濁度として650nmの吸光度を測定し、両測定値の差を用いて細胞賦活作用を評価した。線維芽細胞賦活作用は、サンプルブランクにおける細胞賦活作用を100とした相対値にて評価を行った。その結果を表1に合わせて示す。
[Human dermal fibroblast activation]
Normal human dermal fibroblasts were seeded in a 96-well microplate at 2.0 × 10 4 cells per well. Dulbecco's modified Eagle medium (DMEM) supplemented with 1% by weight fetal bovine serum (FBS) was used as the seeding medium. After 24 hours, the sample culture solution was adjusted to the concentration shown in Table 1 with 1% by mass FBS-added DMEM medium, and further cultured for 48 hours. Next, the MTT reagent adjusted with the culture medium so that it might become 400 micrograms / mL was added to the cell except the supernatant, and it culture | cultivated for about 2 hours. Finally, formazan produced in 2-propanol was extracted and the absorbance at 550 nm was measured. At the same time, the absorbance at 650 nm was measured as turbidity, and the cell activation effect was evaluated using the difference between the two measured values. The fibroblast activation action was evaluated by a relative value with the cell activation action in the sample blank as 100. The results are also shown in Table 1.

Figure 2011148742
Figure 2011148742

表1に示したとおり、フコキサンチンと、アーモンド抽出物若しくはペパーミント抽出物を併用することにより、それぞれを単独で倍量添加した比較例と比較して、相乗的な表皮角化細胞の賦活効果が認められていた。また、フコキサンチンとペパーミント抽出物を併用することにより、それぞれを単独で倍量添加した比較例と比較して、相乗的な真皮線維芽細胞の賦活効果が認められた。   As shown in Table 1, by using fucoxanthin in combination with almond extract or peppermint extract, there is a synergistic activation effect of epidermal keratinocytes compared to the comparative example in which each was added alone. It was recognized. Further, by using fucoxanthin and peppermint extract in combination, a synergistic dermal fibroblast activation effect was observed as compared with the comparative example in which each was added alone.

続いて、上述のフコキサンチンと、アーモンド抽出物若しくはペパーミント抽出物を併用した皮膚外用剤と食品の処方例を示す。   Then, the prescription example of the skin external preparation and foodstuff which used the above-mentioned fucoxanthin and the almond extract or the peppermint extract together is shown.

[処方例1]乳液
(1)スクワラン 10.0(重量%)
(2)メチルフェニルポリシロキサン 4.0
(3)水素添加パーム核油 0.5
(4)水素添加大豆リン脂質 0.1
(5)モノステアリン酸ポリオキシエチレン
ソルビタン(20E.O.) 1.3
(6)モノステアリン酸ソルビタン 1.0
(7)グリセリン 4.0
(8)パラオキシ安息香酸メチル 0.1
(9)カルボキシビニルポリマー 0.15
(10)精製水 57.85
(11)アルギニン(1重量%水溶液) 20.0
(12)フコキサンチン 0.5
(13)アーモンド抽出物 0.5
製法:(1)〜(6)の油相成分を80℃にて加熱溶解する。一方(7)〜(10)の水相成分を80℃にて加熱溶解する。これに前記油相成分を攪拌しながら加え、ホモジナイザーにより均一に乳化する。乳化終了後、冷却を開始し、(11)〜(13)を順次加え、均一に混合する。
[Formulation Example 1] Emulsion (1) Squalane 10.0 (wt%)
(2) Methylphenylpolysiloxane 4.0
(3) Hydrogenated palm kernel oil 0.5
(4) Hydrogenated soybean phospholipid 0.1
(5) Polyoxyethylene monostearate
Sorbitan (20E.O.) 1.3
(6) Sorbitan monostearate 1.0
(7) Glycerin 4.0
(8) Methyl paraoxybenzoate 0.1
(9) Carboxyvinyl polymer 0.15
(10) Purified water 57.85
(11) Arginine (1 wt% aqueous solution) 20.0
(12) Fucoxanthin 0.5
(13) Almond extract 0.5
Production method: The oil phase components (1) to (6) are heated and dissolved at 80 ° C. On the other hand, the aqueous phase components (7) to (10) are dissolved by heating at 80 ° C. The oil phase component is added to this while stirring and uniformly emulsified with a homogenizer. After the emulsification is completed, cooling is started, and (11) to (13) are sequentially added and mixed uniformly.

[処方例2]化粧水
(1)エタノール 15.0(重量%)
(2)ポリオキシエチレン(40E.O.)硬化ヒマシ油 0.3
(3)香料 0.1
(4)精製水 82.38
(5)クエン酸 0.02
(6)クエン酸ナトリウム 0.1
(7)グリセリン 1.0
(8)ヒドロキシエチルセルロース 0.1
(9)フコキサンチン 0.5
(10)ペパーミント抽出物 0.5
製法:(1)に(2)及び(3)を溶解する。溶解後、(4)〜(8)を順次添加した後、十分に攪拌し、(9)、(10)を加え、均一に混合する。
[Prescription Example 2] Lotion (1) Ethanol 15.0 (wt%)
(2) Polyoxyethylene (40E.O.) hydrogenated castor oil 0.3
(3) Fragrance 0.1
(4) Purified water 82.38
(5) Citric acid 0.02
(6) Sodium citrate 0.1
(7) Glycerin 1.0
(8) Hydroxyethyl cellulose 0.1
(9) Fucoxanthin 0.5
(10) Peppermint extract 0.5
Production method: (2) and (3) are dissolved in (1). After dissolution, (4) to (8) are sequentially added, and then sufficiently stirred, and (9) and (10) are added and mixed uniformly.

[処方例3]クリーム
(1)スクワラン 10.0(重量%)
(2)ステアリン酸 2.0
(3)水素添加パーム核油 0.5
(4)水素添加大豆リン脂質 0.1
(5)セタノール 3.6
(6)親油型モノステアリン酸グリセリン 2.0
(7)グリセリン 10.0
(8)パラオキシ安息香酸メチル 0.1
(9)アルギニン(20重量%水溶液) 15.0
(10)精製水 40.7
(11)カルボキシビニルポリマー(1重量%水溶液) 15.0
(12)フコキサンチン 0.4
(13)ペパーミント抽出物 0.3
(14)アーモンド抽出物 0.3
製法:(1)〜(6)の油相成分を80℃にて加熱溶解する。一方(7)〜(10)の水相成分を80℃にて加熱溶解する。これに前記油相成分を攪拌しながら加え、ホモジナイザーにより均一に乳化する。乳化終了後、(11)を加え、冷却を開始し、40℃にて(12)〜(14)を加え、均一に混合する。
[Prescription Example 3] Cream (1) Squalane 10.0 (% by weight)
(2) Stearic acid 2.0
(3) Hydrogenated palm kernel oil 0.5
(4) Hydrogenated soybean phospholipid 0.1
(5) Cetanol 3.6
(6) Lipophilic glyceryl monostearate 2.0
(7) Glycerin 10.0
(8) Methyl paraoxybenzoate 0.1
(9) Arginine (20% by weight aqueous solution) 15.0
(10) Purified water 40.7
(11) Carboxyvinyl polymer (1% by weight aqueous solution) 15.0
(12) Fucoxanthin 0.4
(13) Peppermint extract 0.3
(14) Almond extract 0.3
Production method: The oil phase components (1) to (6) are heated and dissolved at 80 ° C. On the other hand, the aqueous phase components (7) to (10) are dissolved by heating at 80 ° C. The oil phase component is added to this while stirring and uniformly emulsified with a homogenizer. (11) is added after completion | finish of emulsification, cooling is started, (12)-(14) is added at 40 degreeC, and it mixes uniformly.

[処方例4]水性ジェル
(1)カルボキシビニルポリマー 0.5(重量%)
(2)精製水 86.7
(3)水酸化ナトリウム(10重量%水溶液) 0.5
(4)エタノール 10.0
(5)パラオキシ安息香酸メチル 0.1
(6)香料 0.1
(7)フコキサンチン 0.4
(8)ペパーミント抽出物 0.3
(9)アーモンド抽出物 0.3
(10)ポリオキシエチレン(60E.O.)硬化ヒマシ油 0.1
製法:(1)を(2)に加え、均一に攪拌した後、(3)を加える。均一に攪拌した後、(4)に予め溶解した(5)を加える。均一に攪拌した後、予め混合しておいた(6)〜(10)を加え、均一に攪拌混合する。
[Formulation Example 4] Aqueous gel (1) Carboxyvinyl polymer 0.5 (% by weight)
(2) Purified water 86.7
(3) Sodium hydroxide (10% by weight aqueous solution) 0.5
(4) Ethanol 10.0
(5) Methyl paraoxybenzoate 0.1
(6) Fragrance 0.1
(7) Fucoxanthin 0.4
(8) Peppermint extract 0.3
(9) Almond extract 0.3
(10) Polyoxyethylene (60E.O.) hydrogenated castor oil 0.1
Manufacturing method: (1) is added to (2), and after stirring uniformly, (3) is added. After stirring uniformly, (5) previously dissolved in (4) is added. After stirring uniformly, (6) to (10) previously mixed are added and stirred and mixed uniformly.

[処方例5]温感ジェル
(1)グリセリン 97.8(質量%)
(2)カルボキシビニルポリマー 0.5
(3)精製水 0.5
(4)香料 0.1
(5)ポリオキシエチレン(60E.O.)硬化ヒマシ油 0.1
(7)フコキサンチン 0.4
(8)ペパーミント抽出物 0.3
(9)アーモンド抽出物 0.3
製法:全成分を均一に混合攪拌する。
[Prescription Example 5] Warm gel (1) Glycerin 97.8 (% by mass)
(2) Carboxyvinyl polymer 0.5
(3) Purified water 0.5
(4) Fragrance 0.1
(5) Polyoxyethylene (60E.O.) hydrogenated castor oil 0.1
(7) Fucoxanthin 0.4
(8) Peppermint extract 0.3
(9) Almond extract 0.3
Production method: All components are mixed and stirred uniformly.

[処方例6]パック
(1)精製水 62.9(重量%)
(2)ポリビニルアルコール 12.0
(3)エタノール 17.0
(4)グリセリン 5.0
(5)ポリエチレングリコール(平均分子量1000) 2.0
(6)フコキサンチン 0.4
(7)ペパーミント抽出物 0.3
(8)アーモンド抽出物 0.3
(9)香料 0.1
製法:(2)と(3)を混合し、80℃に加温した後、80℃に加温した(1)に溶解する。均一に溶解した後、(4)と(5)を加え、攪拌しながら冷却を開始する。40℃まで冷却し、(6)〜(9)を加え、均一に混合する。
[Formulation Example 6] Pack (1) 62.9 (% by weight) purified water
(2) Polyvinyl alcohol 12.0
(3) Ethanol 17.0
(4) Glycerin 5.0
(5) Polyethylene glycol (average molecular weight 1000) 2.0
(6) Fucoxanthin 0.4
(7) Peppermint extract 0.3
(8) Almond extract 0.3
(9) Fragrance 0.1
Production method: (2) and (3) are mixed, heated to 80 ° C, and then dissolved in (1) heated to 80 ° C. After uniformly dissolving, add (4) and (5), and start cooling while stirring. Cool to 40 ° C., add (6) to (9) and mix uniformly.

[処方例7]錠剤
(1)フコキサンチン 40.0(質量部)
(2)ペパーミント抽出物 30.0
(3)アーモンド抽出物 30.0
(4)トウモロコシデンプン 15.0
(5)グリセリン脂肪酸エステル 12.0
(6)香料 12.0
製法:(1)〜(6)を混合し、常法により打錠して、全量が600mgの錠剤を得た。
[Prescription Example 7] Tablet (1) Fucoxanthin 40.0 (parts by mass)
(2) Peppermint extract 30.0
(3) Almond extract 30.0
(4) Corn starch 15.0
(5) Glycerin fatty acid ester 12.0
(6) Fragrance 12.0
Production method: (1) to (6) were mixed and tableted by a conventional method to obtain a tablet having a total amount of 600 mg.

Claims (2)

成分(A)フコキサンチンと、成分(B)アーモンド及び/又はペパーミントを含有してなる細胞賦活剤。 A cell activator comprising component (A) fucoxanthin and component (B) almond and / or peppermint. 成分(A)フコキサンチンと、成分(B)アーモンド及び/又はペパーミントを含有してなる皮膚外用剤。 An external preparation for skin comprising component (A) fucoxanthin and component (B) almond and / or peppermint.
JP2010012157A 2010-01-22 2010-01-22 Cell activator and skin external preparation Pending JP2011148742A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010012157A JP2011148742A (en) 2010-01-22 2010-01-22 Cell activator and skin external preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2010012157A JP2011148742A (en) 2010-01-22 2010-01-22 Cell activator and skin external preparation

Publications (1)

Publication Number Publication Date
JP2011148742A true JP2011148742A (en) 2011-08-04

Family

ID=44536102

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010012157A Pending JP2011148742A (en) 2010-01-22 2010-01-22 Cell activator and skin external preparation

Country Status (1)

Country Link
JP (1) JP2011148742A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020525491A (en) * 2017-06-30 2020-08-27 アモーレパシフィック コーポレーションAmorepacific Corporation Composition for skin cell damage care by dust containing Mentha albensis extract, skin barrier enhancement, and anti-aging or anti-inflammatory composition
WO2020246468A1 (en) 2019-06-06 2020-12-10 ビタミンC60バイオリサーチ株式会社 Cell activator of animal cell

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1036279A (en) * 1996-07-18 1998-02-10 Ichimaru Pharcos Co Ltd Fibroblast proliferation promoting agent containing vegetable extract
JPH1095735A (en) * 1996-08-02 1998-04-14 Advanced Sukin Res Kenkyusho:Kk Hyaluronic acid productivity potentiator
JP2001163794A (en) * 1999-12-03 2001-06-19 Shiseido Co Ltd Promoter for production of hyaluronic acid and preparation for external use for skin
JP2003267852A (en) * 2002-03-14 2003-09-25 Noevir Co Ltd Cell activator
JP2003342124A (en) * 2002-05-31 2003-12-03 Noevir Co Ltd Skin care preparation
JP2008291004A (en) * 2007-04-26 2008-12-04 Oriza Yuka Kk Composition for beautiful skin
JP2009067701A (en) * 2007-09-11 2009-04-02 Maruzen Pharmaceut Co Ltd Growth promoter of keratinized cell of epidermis and transglutaminase-1 production promoter
JP2009256270A (en) * 2008-04-18 2009-11-05 Maruzen Pharmaceut Co Ltd Insulin-like growth factor-1 expression promoting agent

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1036279A (en) * 1996-07-18 1998-02-10 Ichimaru Pharcos Co Ltd Fibroblast proliferation promoting agent containing vegetable extract
JPH1095735A (en) * 1996-08-02 1998-04-14 Advanced Sukin Res Kenkyusho:Kk Hyaluronic acid productivity potentiator
JP2001163794A (en) * 1999-12-03 2001-06-19 Shiseido Co Ltd Promoter for production of hyaluronic acid and preparation for external use for skin
JP2003267852A (en) * 2002-03-14 2003-09-25 Noevir Co Ltd Cell activator
JP2003342124A (en) * 2002-05-31 2003-12-03 Noevir Co Ltd Skin care preparation
JP2008291004A (en) * 2007-04-26 2008-12-04 Oriza Yuka Kk Composition for beautiful skin
JP2009067701A (en) * 2007-09-11 2009-04-02 Maruzen Pharmaceut Co Ltd Growth promoter of keratinized cell of epidermis and transglutaminase-1 production promoter
JP2009256270A (en) * 2008-04-18 2009-11-05 Maruzen Pharmaceut Co Ltd Insulin-like growth factor-1 expression promoting agent

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
フコキサンチン, JPN6013053761, 19 October 2008 (2008-10-19), pages 1 - 32, ISSN: 0002667712 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020525491A (en) * 2017-06-30 2020-08-27 アモーレパシフィック コーポレーションAmorepacific Corporation Composition for skin cell damage care by dust containing Mentha albensis extract, skin barrier enhancement, and anti-aging or anti-inflammatory composition
JP7158426B2 (en) 2017-06-30 2022-10-21 アモーレパシフィック コーポレーション An anti-aging or anti-inflammatory composition for care of skin cell damage caused by fine dust, for strengthening skin barrier and anti-aging or anti-inflammatory composition containing Mentha arvensis extract
WO2020246468A1 (en) 2019-06-06 2020-12-10 ビタミンC60バイオリサーチ株式会社 Cell activator of animal cell
KR20220003051A (en) 2019-06-06 2022-01-07 비타민 씨60 바이오리서치 가부시키가이샤 cell activator of animal cells

Similar Documents

Publication Publication Date Title
JP2011088845A (en) Involucrin expression inhibitor
JP5557414B2 (en) Moisturizer, cell activator, and whitening agent
JP2008303147A (en) External preparation for skin
JP5014343B2 (en) Nemagaridake-containing composition, moisturizer, cell activator, whitening agent and antioxidant
JP2011148742A (en) Cell activator and skin external preparation
JP5312731B2 (en) Topical skin preparation
JP2009185007A (en) Promoting agent for production of keratinocyte growth factor
JP5062980B2 (en) Moisturizer, collagen production promoter, whitening agent, antioxidant, and vascular endothelial growth factor production promoter
JP2008094792A (en) Hyaluronic acid synthesis promoter, anti-aging agent and skin care preparation each containing commelina communis var. hortensis-derived flavonoid
JP5800454B2 (en) External preparation for skin, oral preparation, antioxidant, anti-aging agent, and immunostimulant
JP5025201B2 (en) Moisturizer, anti-aging agent, whitening agent, anti-inflammatory agent, and antioxidant
JP2009292742A (en) Humectant, anti-aging agent, anti-oxidizing agent and external preparation for skin
JP2007277100A (en) Humectant, cell activator, dermal fibroblast activator, epidermal cell activator, collagen production accelerator, antioxidant, anti-aging agent, beautifully whitening agent or melanin production inhibitor
JP4748962B2 (en) Moisturizer, cell activator, whitening agent, and antioxidant
JP4334956B2 (en) Cell activators, whitening agents, and antioxidants
JP4970442B2 (en) Whitening agent
JP4480366B2 (en) Cell activator, whitening agent, hyaluronic acid production promoter, collagen production promoter, antioxidant, and skin external preparation
JP4994684B2 (en) Moisturizer, cell activator, and antioxidant
JP4050727B2 (en) Moisturizer, cell activator, whitening agent, antioxidant, and skin external preparation
JP4931452B2 (en) Moisturizer, cell activator, whitening agent, and antioxidant
JP4291647B2 (en) Cell activator, whitening agent, collagen production promoter, antioxidant, and skin external preparation
JP5656348B2 (en) Moisturizer, anti-aging agent, antioxidant, immunostimulant, whitening agent, skin external preparation, functional oral composition
JP4916150B2 (en) Moisturizer, cell activator, antioxidant, and skin external preparation,
JP5013726B2 (en) Moisturizer, cell activator, antioxidant, and collagenase inhibitor
JP4936754B2 (en) Moisturizer, cell activator, and collagenase inhibitor

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120802

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140617